RxDoctor Payments Data

Asim Razzaq, MD

Urology · Saint Peters, MONPI 1164531877

Payments from drug & device makers

$4,750in general payments, 2019–2025

Across 207 payments — averaging $22.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$646
  • Sumitomo Pharma America, Inc.$608
  • Boston Scientific$450
  • Urogen Pharma, Inc.$402
  • Accord Healthcare, Inc.$335
  • Myriad Genetic Laboratories, Inc.$242
  • plus $2K from 27 others

What the payments were for

  • Food & beverage$4,71599%
  • Education$351%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,750 in reported general payments places this provider in the 50th percentile of 250 urology providers in Missouri.

See all urology providers in Missouri

Medicare billing

Part B allowed, 2024
$246,339
Medicare patients
565
Services billed
5,613

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron197$168,283
MyrbetriqMirabegron138$119,160
XyostedTestosterone Enanthate24$19,356
Mirabegron ErMirabegron23$14,309
Tamsulosin Hcl875$12,784
Finasteride551$7,848
Trospium Chloride ErTrospium Chloride41$5,310
Potassium Citrate ErPotassium Citrate50$4,633
Tadalafil45$4,193
Testosterone11$3,483
Solifenacin Succinate68$3,467
Methenamine Hippurate39$2,998
Silodosin30$2,909
Oxybutynin Chloride ErOxybutynin Chloride119$2,713
Estradiol32$2,002

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$608$168,283197 claims
Astellas Pharma US IncMyrbetriq$646$119,160138 claims
Antares Pharma, Inc.Xyosted$226$19,35624 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 250 urology providers in Missouri.

Other urology in Saint Peters

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →